Nature Medicine (journal)

January 13, 2020

Vanderbilt-led team discovers new genetic disease and defines underlying mechanism

An international research team has discovered a new genetic syndrome caused by mutation of a single gene and named it CATIFA, an acronym for its core symptoms.

By Leigh MacMillan
July 22, 2019

Encephalitis identified as rare toxicity of immunotherapy treatment

Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

By Tom Wilemon
July 18, 2019

Genetic characteristics of peripheral artery disease studied

New study explores why some people with peripheral artery disease present with problems with their legs, some with their heart and some with strokes.

By Matt Batcheldor
September 6, 2018

Team’s findings could spur new treatments for type 2 diabetes

An international research team including scientists from Vanderbilt University has discovered how the diabetes drug metformin blocks glucose production by the liver. The discovery, reported Aug. 27 in the journal Nature Medicine, could lead to development of new ways to treat type 2 diabetes.

By Bill Snyder
January 16, 2018

VUMC researchers find a way to ‘starve’ cancer

Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.

By Bill Snyder
October 17, 2017

Researchers find novel mechanism of resistance to anti-cancer drugs

Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported this week in Nature Medicine, suggest a strategy for overcoming this resistance.

By Leigh MacMillan
September 26, 2016

Study shows excess dietary zinc worsens C. diff infection

Too much dietary zinc increases susceptibility to infection by Clostridium difficile — “C. diff” — the most common cause of hospital-acquired infections.
By Leigh MacMillan
September 4, 2014

Lung cancer study reveals new drug combination targets

A Vanderbilt lung cancer patient’s exceptional response to different types of therapies spurred research that suggests lung cancer patients with specific gene alterations may benefit from combination therapy that targets two different cancer pathways.
By VUMC News and Communications
August 7, 2014

Novel treatment strengthens bones in genetic disease

An enzyme therapy may prevent skeletal abnormalities associated with the genetic disorder neurofibromatosis type-1, Vanderbilt investigators have discovered.
By Leigh MacMillan
1 2